blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3765601

EP3765601 - B CELLS GENETICALLY ENGINEERED TO SECRETE FOLLISTATIN AND METHODS OF USING THE SAME TO TREAT FOLLISTATIN-RELATED DISEASES, CONDITIONS, DISORDERS AND TO ENHANCE MUSCLE GROWTH AND STRENGTH [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  27.10.2023
Database last updated on 26.07.2024
FormerRequest for examination was made
Status updated on  18.12.2020
FormerThe international publication has been made
Status updated on  21.09.2019
Formerunknown
Status updated on  12.04.2019
Most recent event   Tooltip05.03.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Immusoft Corporation
454 N 34th Street
Seattle, WA 98103 / US
[2021/03]
Inventor(s)01 / SCHOLZ, Matthew Rein
c/o Immusoft Corporation 454 N. 34th Street
Seattle, Washington 98103 / US
02 / HERBIG, Eric J.
c/o Immusoft Corporation 454 N. 34th Street
Seattle, Washington 98103 / US
03 / MCIVOR, R. Scott
c/o Immusoft Corporation 454 N. 34th Street
Seattle, Washington 98103 / US
 [2021/03]
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[2021/03]
Application number, filing date19714953.718.03.2019
[2021/03]
WO2019US22821
Priority number, dateUS201862644362P16.03.2018         Original published format: US 201862644362 P
US201862644356P16.03.2018         Original published format: US 201862644356 P
[2021/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019178613
Date:19.09.2019
Language:EN
[2019/38]
Type: A1 Application with search report 
No.:EP3765601
Date:20.01.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 19.09.2019 takes the place of the publication of the European patent application.
[2021/03]
Search report(s)International search report - published on:EP19.09.2019
ClassificationIPC:C12N5/0781, C07K14/47, A61K35/17, A61P21/00, C12N15/64
[2021/03]
CPC:
C12N5/0635 (EP,US); A61K35/16 (US); A61K38/1709 (EP);
A61K39/4612 (EP); A61K39/4622 (EP); A61K39/464402 (EP);
A61K9/0019 (US); A61P21/00 (EP,US); C07K14/4703 (EP);
C12N5/10 (US); A61K2239/31 (EP); A61K2239/38 (EP);
C12N2510/02 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/03]
TitleGerman:GENETISCH MANIPULIERTE B-ZELLEN ZUR SEZERNIERUNG VON FOLLISTATIN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG VON FOLLISTATINBEDINGTEN KRANKHEITEN, LEIDEN, STÖRUNGEN UND ZUR ERHÖHUNG DES MUSKELWACHSTUMS UND DER MUSKELKRAFT[2021/03]
English:B CELLS GENETICALLY ENGINEERED TO SECRETE FOLLISTATIN AND METHODS OF USING THE SAME TO TREAT FOLLISTATIN-RELATED DISEASES, CONDITIONS, DISORDERS AND TO ENHANCE MUSCLE GROWTH AND STRENGTH[2021/03]
French:LYMPHOCYTES B GÉNÉTIQUEMENT MODIFIÉES POUR SÉCRÉTER DE LA FOLLISTATINE ET LEURS MÉTHODES D'UTILISATION POUR TRAITER DES MALADIES, DES ÉTATS, DES TROUBLES LIÉS À LA FOLLISTATINE ET POUR AMÉLIORER LA CROISSANCE ET LA RÉSISTANCE MUSCULAIRES[2021/03]
Entry into regional phase13.10.2020National basic fee paid 
13.10.2020Designation fee(s) paid 
13.10.2020Examination fee paid 
Examination procedure13.10.2020Examination requested  [2021/03]
13.10.2020Date on which the examining division has become responsible
03.05.2021Amendment by applicant (claims and/or description)
26.10.2023Despatch of a communication from the examining division (Time limit: M04)
05.03.2024Reply to a communication from the examining division
Fees paidRenewal fee
12.03.2021Renewal fee patent year 03
16.02.2022Renewal fee patent year 04
14.02.2023Renewal fee patent year 05
03.01.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]US7887793  (TREMBLAY JACQUES P [CA], et al) [A] 1-85* examples 10-15 *;
 [ID]US2016083440  (MINEAU ROCHELLE [US]) [ID] 1-5,14-18,21,32-34 * page 1 - page 2; claim 27 *;
 [A]WO2016057975  (RES INST NATIONWIDE CHILDRENS HOSPITAL [US]) [A] 1-85 * paragraph [[0019]]; claim 1 *;
 [A]US2016256526  (KUMAR RAVINDRA [US], et al) [A] 1-85 * page 1 - page 2 *;
 [A]  - B. F. BENABDALLAH ET AL, "Overexpression of Follistatin in Human Myoblasts Increases Their Proliferation and Differentiation, and Improves the Graft Success in SCID Mice", CELL TRANSPLANTATION, US, (20090701), vol. 18, no. 7, doi:10.3727/096368909X470865, ISSN 0963-6897, pages 709 - 718, XP055588847 [A] 1-85 * page 709; figure 2 *

DOI:   http://dx.doi.org/10.3727/096368909X470865
 [A]  - CHUNXIA ZHAO ET AL, "Overcoming Insulin Insufficiency by Forced Follistatin Expression in [beta] -cells of db/db Mice", MOLECULAR THERAPY, GB, (20150501), vol. 23, no. 5, doi:10.1038/mt.2015.29, ISSN 1525-0016, pages 866 - 874, XP055525294 [A] 1-85 * page 871 - page 873 *

DOI:   http://dx.doi.org/10.1038/mt.2015.29
 [A]  - JANAIAH KOTA ET AL, "Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE (A A A S), US, (20091111), vol. 1, no. 6, doi:10.1126/SCITRANSLMED.3000112, ISSN 1946-6242, pages 6ra15 - 1, XP002752988 [A] 1-85 * page 1 - page 3 *

DOI:   http://dx.doi.org/10.1126/scitranslmed.3000112
 [A]  - MENDELL J R ET AL, "A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 23, no. 1, doi:10.1038/MT.2014.200, ISSN 1525-0024, (20150101), pages 192 - 201, (20141017), XP002752989 [A] 1-85 * page 192 *

DOI:   http://dx.doi.org/10.1038/mt.2014.200
by applicantFR901228
 US4937190
 US5124259
 US5283185
 US5297983
 US5420032
 US5626561
 US5661018
 US5787900
 US5843069
 US5902745
 US5913998
 US5980889
 US6013516
 US6218181
 US2003115614
 US2003232410
 US6833252
 US2005026157
 US2005064474
 US6878548
 US2005208489
 US2006063231
 US2006188987
 WO2007014275
 US2007117128
 US2009117617
 US2009263900
 US2010047805
 US2010203630
 US7799555
 WO2011085247
 US2011207221
 US2011301073
 US8551780
 US8633029
 WO2014152832
 WO2016100932
    - EMERY, The Lancet, (20020000), vol. 359, pages 687 - 695
    - KHURANA et al., Nat. Rev. Drug Discovery, (20030000), vol. 2, pages 279 - 386
    - GROBET et al., Nat. Genet., (19970000), vol. 17, no. 1, pages 71 - 4
    - SCHUELKE et al., N Engl J Med, (20040000), vol. 350, pages 2682 - 8
    - LEE, SJ; MCPHERRON, AC, Proc Natl Acad Sci USA., (20010731), vol. 98, no. 16, pages 9306 - 11
    - KOTA J et al., Sci Transl Med., (20091111), vol. 1, no. 6
    - DNA Cloning: A Practical Approach, vol. I, II
    - Trends Immunol., (20090600), vol. 30, no. 6, pages 277 - 285
    - Nature Reviews, (20050000), vol. 5, pages 231 - 242
    - JOURDAN et al., Blood, (20091210), vol. 114, no. 25, pages 5173 - 81
    - Nature Med., (20100000), vol. 16, pages 123 - 129
    - NEUBERGER, M. S.; HONJO, T.; ALT, FREDERICK W., Molecular biology of B cells, Elsevier, (20040000), pages 189 - 191
    - BERTIL GLADER; GREER, JOHN G.; JOHN FOERSTER; RODGERS, GEORGE G.; PARASKEVAS, FRIXOS, Wintrobe's Clinical Hematology, Lippincott Williams & Wilkins, (20080000), vol. 2, page 347
    - WALPORT, MARK; MURPHY, KENNETH; JANEWAY, CHARLES; TRAVERS, PAUL J., Janeway's immunobiology, Garland Science, (20080000), pages 387 - 388
    - DEFRANCO et al., J. Exp. Med., (19820000), vol. 155, page 1523
    - FLUCKIGER et al., Blood, (19980000), vol. 92, pages 4509 - 4520
    - LUO et al., Blood, (20090000), vol. 1, no. 13, pages 1422 - 1431
    - R.H. ARCH et al., Genes Dev., (19980000), vol. 12, pages 2821 - 2830
    - NERON et al., PLoS ONE, (20120000), vol. 7, no. 12, page e51946
    - CIVIN CI; LOKEN MR, Int'l J. Cell Cloning, vol. 987, no. 5, pages 1 - 16
    - "Flow Cytometry Characterization of Erythroid, Lymphoid and Monomyeloid Lineages in Normal Human Bone Marrow", LOKEN, MR et al., Flow Cytometry in Hematology, Academic Press, (19920000), pages 31 - 42
    - LEBEIN TW et al., Leukemia, (19900000), vol. 4, pages 354 - 358
    - NOELLE et al., J. Immunol., (19910000), vol. 146, pages 1118 - 1124
    - GRAHAM et al., Virology, (19730000), vol. 52, page 456
    - CHU et al., Gene, (19810000), vol. 13, page 197
    - KOLLER et al., Proc. Nat'l. Acad. Sci. USA, (19890000), vol. 86, no. 22, pages 8927 - 8931
    - THOMAS et al., Cell, (19860000), vol. 44, no. 3, pages 419 - 428
    - HOCKEMEYER et al., Nature Biotech., (20090000), vol. 27, no. 9, pages 851 - 857
    - LOMBARDO et al., Nature Biotech., (20070000), vol. 25, no. 11, pages 1298 - 1306
    - MOEHLE et al., Proc. Nat'l Acad. Sci. USA, (20070000), vol. 104, no. 9, pages 3055 - 3060
    - ROUET et al., Proc. Nat'l Acad. Sci. USA, (19940000), vol. 91, no. 13, pages 6064 - 6068
    - BURGESS, Nature Reviews Genetics, (20130000), vol. 14, pages 80 - 81
    - URNOV et al., Nature, (20100000), vol. 435, no. 7042, pages 646 - 51
    - KIM et al., Proc Natl Acad Sci USA, (19960000), vol. 93, no. 3, pages 1156 - 1160
    - JINEK et al., Science, (20120000), vol. 337, pages 816 - 821
    - JINEK et al., eLife, (20130000), vol. 2, page e00471
    - DAVID SEGAL, eLife, (20130000), vol. 2, page e00563
    - SCHORNACK S et al., J Plant Physiol, (20060000), vol. 163, no. 3, pages 256 - 272
    - BONAS et al., Mol Gen Genet, (19890000), vol. 218, pages 127 - 136
    - BELFORT et al., Nucleic Acids Res., (19970000), vol. 25, pages 3379 - 3388
    - DUJON et al., Gene, (19890000), vol. 82, pages 115 - 118
    - PERLER et al., Nucleic Acids Res., (19940000), vol. 22, pages 1125 - 1127
    - JASIN, Trends Genet., (19960000), vol. 12, pages 224 - 228
    - GIMBLE et al., J. Mol. Biol., (19960000), vol. 263, pages 163 - 180
    - ARGAST et al., J. Mol. Biol., (19980000), vol. 280, pages 345 - 353
    - CHEVALIER et al., Molec. Cell, (20020000), vol. 10, pages 895 - 905
    - EPINAT et al., Nucleic Acids Res., (20030000), vol. 31, pages 2952 - 2962
    - ASHWORTH et al., Nature, (20060000), vol. 441, pages 656 - 659
    - PAQUES et al., Current Gene Therapy, (20070000), vol. 7, pages 49 - 66
    - HACKETT P.B. et al., "Evaluating Risks of Insertional Mutagenesis by DNA Transposons in Gene Therapy", Transl Res., (20130400), vol. 161, no. 4, pages 265 - 283
    - HUDECEK M et al., "Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side", Crit Rev Biochem Mol Biol., (20170800), vol. 52, no. 4, doi:doi:10.1080/10409238.2017.1304354, pages 355 - 380, XP055541375

DOI:   http://dx.doi.org/10.1080/10409238.2017.1304354
    - KRISKY, Gene Ther., (19980000), vol. 5, pages 1517 - 30
    - PFEIFER, Annu. Rev. Genomics Hum. Genet., (20010000), vol. 2, pages 177 - 211
    - Science, (19960412), vol. 272, pages 263 - 267
    - Blood, (20070000), vol. 99, pages 2342 - 2350
    - Blood, (20090000), vol. 1, no. 13, pages 1422 - 1431
    - Blood, (20091008), vol. 14, no. 15, pages 3173 - 80
    - Blood, (20030000), vol. 101, no. 6, pages 2167 - 2174
    - HAWLEY et al., PNAS USA, (19960000), vol. 93, pages 10297 - 10302
    - KELLER et al., Blood, (19980000), vol. 92, pages 877 - 887
    - CHOI et al., Stem Cells, (20010000), vol. 19, pages 236 - 246
    - EVANS et al., Hum Gene Ther., (19990000), vol. 10, pages 1479 - 1489
    - CASE et al., PNAS USA, (19990000), vol. 96, pages 2988 - 2993
    - UCHIDA et al., PNAS USA, (19980000), vol. 95, no. 1, pages 1939 - 11944
    - MIYOSHI et al., Science, (19990000), vol. 283, pages 682 - 686
    - SUTTON et al., J Virol, (19980000), vol. 72, pages 5781 - 5788
    - FRECHA et al., Blood, (20080000), vol. 1, no. 12, pages 4843 - 52
    - FRECHA et al., Mol. Therapy, (20100000), vol. 18, page 1748
    - O NARAYAN, J. Gen. Virology, (19890000), vol. 70, pages 1617 - 1639
    - MIYOSHI et al., J Virol., (19980000), vol. 72, pages 8150 - 7
    - ZUFFEREY et al., J Virol., (19980000), vol. 72, pages 9873 - 9880
    - MIYOSHI et al., J Virol., (19980000), vol. 72, pages 8150 - 8157
    - IWAKUMA et al., J Virology, (19990000), vol. 261, pages 120 - 132
    - TEY et al., Biology of Blood and Marrow Transplantation, (20070000), vol. 13, pages 913 - 924
    - LAUER et al., Cancer Gene Ther., (20000300), vol. 7, no. 3, pages 430 - 7
    - PAULE; WHITE, Nucleic Acids Research, (20000000), vol. 28, pages 1283 - 1298
    - OHKAWA; TAIRA, Human Gene Therapy, (20000000), vol. 11, pages 577 - 585
    - MEISSNER et al., Nucleic Acids Research, (20010000), vol. 29, pages 1672 - 1682
    - KARASUYAMA et al., J. Exp. Med., (19890000), vol. 169, page 13
    - GUNNING et al., PNAS USA, (19870000), vol. 84, pages 4831 - 4835
    - ADRA et al., Gene, (19870000), vol. 60, pages 65 - 74
    - SINGER-SAM et al., Gene, (19840000), vol. 32, pages 409 - 417
    - DOBSON et al., Nucleic Acids Res., (19820000), vol. 10, pages 2635 - 2637
    - GARVIN et al., Mol. Cell Biol., (19880000), vol. 8, pages 3058 - 3064
    - TAKADERA et al., Mol. Cell Biol., (19890000), vol. 9, pages 2173 - 2180
    - YEE et al., Genes and Development, (19930000), vol. 7, pages 1277 - 1289
    - GUNDERSEN et al., Gene, (19920000), vol. 1, no. 13, pages 207 - 214
    - FAN et al., Human Gene Therapy, (19990000), vol. 10, pages 2273 - 2285
    - LE et al., Virus Genes, (19960000), vol. 12, pages 135 - 147
    - LE et al., Nuc. Acids Res., (19970000), vol. 25, pages 362 - 369
    - ZUFFEREY et al., J. Virol., (19990000), vol. 74, pages 3668 - 3681
    - DEGLON et al., Hum. Gene Ther., (20000000), vol. 11, pages 179 - 190
    - ZHANG F et al., Molecular Therapy: The journal of the American Society of Gene Therapy, (20100900), vol. 18, no. 9, pages 1640 - 9
    - FRECHA et al., Blood, (20090000), vol. 1, no. 14, pages 3173 - 80
    - PNAS, U.S.A., (19880000), vol. 85, no. 12, pages 4218 - 4222
    - "NCBI", Database accession no. AAH04107.1
    - NAKATANI et al., The FASEB Journal, (20080000), vol. 22477-48
    - DNA Cloning, IRL Press, (19850000), vol. I ; II
    - GLUZMAN, Cell, (19810000), vol. 23, page 175
    - ROSENBERG et al., New Eng. J. of Med., (19880000), vol. 319, page 1676
    - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533
    - SEFTON, CRC Crit. Ref. Biomed. Eng., (19870000), vol. 14, page 201
    - BUCHWALD et al., Surgery, (19800000), vol. 88, page 507
    - SAUDEK et al., N. Engl. J. Med., (19890000), vol. 321, page 574
    - RANGER; PEPPAS, J. Macromol. Sci. Rev. Macromol. Chem., (19830000), vol. 23, page 61
    - LEVY et al., Science, (19850000), vol. 228, page 190
    - DURING et al., Ann. Neurol., (19890000), vol. 25, page 351
    - HOWARD et al., J. Neurosurg, (19890000), vol. 71, page 105
    - Medical Applications of Controlled Release, CRC Pres., (19840000), vol. 2, pages 115 - 138
    - LIU et al., Cell, (19910000), vol. 66, pages 807 - 815
    - HENDERSON et al., Immun., (19910000), vol. 73, pages 316 - 321
    - BIERER et al., Curr. Opin. Immun., (19930000), vol. 5, pages 763 - 773
    - KHURANA et al., Nat. Rev. Drug Disc., (20030000), vol. 2, pages 379 - 386
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.